LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

Home・Elenco Azioni・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Chiusa

SettoreSettore sanitario

12.06 -4.29

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

11.88

Massimo

12.67

Metriche Chiave
By Trading Economics
Entrata	227M
Vendite	139M
P/E Media del settore	4.857 51.415
Margine di Profitto	163.843
Dipendenti	1,796
EBITDA	1.3M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+57.85% upside

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	2.2B
Apertura precedente	16.35
Chiusura precedente	12.06

Notizie sul Sentiment di mercato

By Acuity

50%

171 / 346 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

14.24 / 14.78 Supporto e resistenza

Hutchison China MediTech Ltd ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

14 mag 2026, 22:44 UTC

Acquisizioni, Fusioni, Takeovers

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

14 mag 2026, 22:27 UTC

Acquisizioni, Fusioni, Takeovers

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

14 mag 2026, 22:12 UTC

Utili

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

14 mag 2026, 21:52 UTC

Acquisizioni, Fusioni, Takeovers

LVMH to Sell Marc Jacobs

15 mag 2026, 00:00 UTC

Utili

Honda's Never Faced a Crisis Like This -- And a Comeback Won't Be Easy -- WSJ

14 mag 2026, 23:57 UTC

Acquisizioni, Fusioni, Takeovers

Kakao: Stake Sales Aim to Secure Funds for Future Investments

14 mag 2026, 23:56 UTC

Acquisizioni, Fusioni, Takeovers

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

14 mag 2026, 23:56 UTC

Acquisizioni, Fusioni, Takeovers

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

14 mag 2026, 23:56 UTC

Discorsi di Mercato

Gold Prices Rise on Strong Demand -- Market Talk

14 mag 2026, 23:56 UTC

Acquisizioni, Fusioni, Takeovers

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

14 mag 2026, 23:50 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

14 mag 2026, 23:50 UTC

Discorsi di Mercato

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

14 mag 2026, 23:47 UTC

Utili

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

14 mag 2026, 23:47 UTC

Utili

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

14 mag 2026, 23:46 UTC

Utili

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

14 mag 2026, 23:46 UTC

Utili

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

14 mag 2026, 23:28 UTC

Discorsi di Mercato

New Zealand's Economy Faltering Amid Shocks -- Market Talk

14 mag 2026, 23:00 UTC

Discorsi di Mercato

Australia's One Nation Party Leads In The Polls -- Market Talk

14 mag 2026, 22:46 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

14 mag 2026, 22:46 UTC

Discorsi di Mercato

Court Decision 'Negative But Balanced' for Coles -- Market Talk

14 mag 2026, 22:46 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

14 mag 2026, 22:35 UTC

Discorsi di Mercato

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

14 mag 2026, 22:11 UTC

Acquisizioni, Fusioni, Takeovers

LVMH Agrees to Sell Marc Jacobs -- WSJ

14 mag 2026, 22:06 UTC

Discorsi di Mercato

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

14 mag 2026, 22:04 UTC

Utili

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

14 mag 2026, 22:04 UTC

Utili

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

14 mag 2026, 22:04 UTC

Utili

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

14 mag 2026, 22:00 UTC

Utili

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

14 mag 2026, 21:55 UTC

Utili

Nu Holdings 1Q EPS 18c >NU

14 mag 2026, 21:55 UTC

Utili

Nu Holdings 1Q Rev $4.97B >NU

Confronto tra pari

Modifica del prezzo

Hutchison China MediTech Ltd ADR Previsione

Obiettivo di Prezzo

By TipRanks

57.85% in crescita

Previsioni per 12 mesi

Media 20 USD 57.85%

Alto 20 USD

Basso 20 USD

Basato su 1 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Hutchison China MediTech Ltd ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

1 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 1 che hanno fornito valutazioni azionarie a Hutchison China MediTech Ltd ADR - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

14.24 / 14.78Supporto e resistenza

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

171 / 346 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.